Teva Pharmaceutical Industries' (TEVA) Buy Rating Reiterated at Canaccord Genuity

Teva Pharmaceutical Industries' (TEVA) Buy Rating Reiterated at Canaccord Genuity


Several other research firms have also recently weighed in on TEVA. Guggenheim reiterated a "buy" rating and issued a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, April 19th.



from Biotech News